Yıl: 2011 Cilt: 11 Sayı: 7 Sayfa Aralığı: 582 - 587 Metin Dili: Türkçe

Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study

Öz:
Amaç: Yavaş koroner akım (YKA) önemli darlık olmaksızın epikardiyal koroner arterlerin geç opasifiye olmasıdır. Yavaş koroner akım oluşumundaki temel mekanizma koroner ateroskleroza benzer ve serbest radikal oluşumu patolojiden sorumlu olabilir. Biz bu çalışmada, normal koroner arterli hastalarla, daralma olmaksızın YKA bulunan hastalar arasında iskemi-modifiye albümin (İMA) seviyeleri ve total antioksidan durum (TAD) açısından farklılık olup olmadığını araştırdık. Yöntemler: Koroner anjiyografi sırasında YKA bulunan 30 ardışık hasta (13 erkek; ortalama yaş 56±10 yıl) ile normal koroner artere sahip olup YKA olmayan 30 kişi (13 erkek; ortalama yaş 53±11 yıl) kontrol grubu olarak bu gözlemsel enine-kesitli çalışmaya alındı. Bu çalışmada serum İMA seviyeleri, albümine göre düzeltilmiş İMA ve TAD ölçüldü. İki grup arasında serum İMA seviyeleri ve TAD’ı değerlendirmek için Student t-testi kullanıldı. Serum İMA seviyeleri ve TAD arasındaki ilişkiyi açıklamak için Pearson korelasyon testi uygulandı. Bulgular: Serum İMA seviyeleri ve albümine göre düzeltilmiş İMA her iki grupta benzerdi (p=0.432, p=0.349). Ortalama TAD değeri YKA grubunda kontrol grubuna göre daha düşük bulundu (p=0.011). Yavaş koroner akım hastalarında TAD ile serum İMA seviyeleri ve albümine göre düzeltilmiş İMA arasında negatif ilişki tespit edildi (r=-0.457, p=0.011; r=-0.509, p=0.004). Sonuç: Bu çalışma göstermiştir ki, serum İMA seviyeleri ve albümine göre düzeltilmiş İMA gruplar arasında benzerken, ortalama TAD değeri YKA grubunda kontrol grubundan daha düşük ve İMA ile negatif olarak ilişkilidir. Bu sonuçlar YKA patofizyolojisini anlamak için önemli bulunmuştur.
Anahtar Kelime:

Konular:
Fen > Tıp > Kalp ve Kalp Damar Sistemi

Yavaş koroner akımın görüldüğü hastalarda iskeminin değişikliğe uğrattığı albümin ve total antioksidan durum: Gözlemsel bir pilot çalışma

Öz:
Objective: Slow coronary flow (SCF) is defined as late opacification in the epicardial coronary arteries without significant stenosis. The underlying mechanism of SCF is similar to coronary atherosclerosis. Free radical damage may be responsible for the pathology. In this study, we aimed to investigate ischemia-modified albumin (IMA) levels and differences with regard to total antioxidant status (TAS) between patients with normal coronary arteries and patients with SCF without significant stenosis. Methods: Thirty patients who were diagnosed with SCF using coronary angiography were included in this cross-sectional observational study (13 male; mean age, 56±10 years). The control group consisted of 30 patients who had normal coronary arteries as shown by coronary angiography (13 male; mean age, 53±11 years). In this study, we assessed serum IMA levels, albumin-adjusted IMA and TAS. The Student t-test was used to compare serum IMA levels and TAS between the two groups. Pearson’s correlation test was used to explore the relationship between TAS and serum IMA levels. Results: Serum IMA levels and albumin-adjusted IMA were similar in both groups (p=0.432, p=0.349). The mean value of TAS was significantly lower in the SCF group compared to control group (p=0.011). The TAS was negatively correlated with the levels of IMA and albumin-adjusted IMA in the SCF group (r=-0.457, p=0.011; r=-0.509, p=0.004). Conclusion: This study shows that serum IMA levels and albumin-adjusted IMA were similar between the groups, however the mean value of TAS was significantly lower in the SCF group compared to control group and negatively correlated with IMA. These results are important in terms of understanding the pathophysiological basis of SCF.
Anahtar Kelime:

Konular:
Fen > Tıp > Kalp ve Kalp Damar Sistemi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Çamsarı A, Özcan T, Özer C, Akçay B. Carotid artery intima-media thickness correlates with intravascular ultrasound parameters in patients with slow coronary flow. Atherosclerosis 2008; 200: 310-4. [CrossRef]
  • 2. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding. Am Heart J 1972; 84: 66-71. [CrossRef]
  • 3. Shirani S, Darabian S, Jozaghi S, Hamidian R. Correlation between endothelial dysfunction in normal coronary patients with slow flow and aortic ectasia: the first report. Cardiol J 2009; 16: 146-50.
  • 4. Erdoğan D, Calışkan M, Güllü H, Sezgin AT, Yıldırır A, Müderrisoğlu H. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis 2007; 191: 168-74.
  • 5. Fineschi M, Bravi A, Gori T. The “slow coronary flow” phenomenon: evidence of preserved coronary flow reserve despite increased resting microvascular resistances. Int J Cardiol 2008; 127: 358-61. [CrossRef]
  • 6. Sezgin AT, Sığırcı A, Barutçu I, Topal E, Sezgin N, Özdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14: 155-61. [CrossRef]
  • 7. Şen N, Özlü MF, Başar N, Özcan F, Güngör O, Turak O, et al. Relationship between elevated serum gamma-glutamyltransferase activity and slow coronary flow. Türk Kardiyol Dern Arş 2009; 37: 168-73.
  • 8. Akçay A, Acar G, Kurutaş E, Sökmen A, Atlı Y, Nacar AB, et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Türk Kardiyol Dern Arş 2010; 38: 244-9.
  • 9. Thérond P, Bonnefont-Rousselot D, Davit-Spraul A, Conti M, Legrand A. Biomarkers of oxidative stress: an analytical approach. Curr Opin Clin Nutr Metab Care 2000; 3: 373-84.
  • 10. Flores-Mateo G, Carrillo-Santisteve P, Elosua R, Guallar E, Marrugat J, Bleys J, et al. Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am J Epidemiol 2009; 170: 135-47. [CrossRef]
  • 11. Jain AP, Mohan A, Gupta OP, Jajoo UN, Kalantri SP, Srivastava LM. Role of oxygen free radicals in causing endothelial damage in acute myocardial infarction. J Assoc Physicians India 2000; 48: 478-80.
  • 12. LoPresti R, Catania A, D'Amico T, Montana M, Caruso M, Caimi G. Oxidative stress in young subjects with acute myocardial infarction: evaluation at the initial stage and after 12 months. Clin Appl Thromb Hemost 2008; 14: 421-7. [CrossRef]
  • 13. Kazanis K, Dalamaga M, Nounopoulos C, Manolis AS, Sakellaris N, Jullien G, et al. Ischemia modified albumin, high-sensitivity C-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. Clin Chim Acta 2009; 408: 65-9. [CrossRef]
  • 14. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemiamodified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107: 2403-5. [CrossRef]
  • 15. Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin-I. Am Heart J 2001; 141: 985-91. [CrossRef]
  • 16. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of ‘‘ischemia-modified albumin’’, a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29-34. [CrossRef]
  • 17. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 2006; 92: 113-4. [CrossRef]
  • 18. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88.
  • 19. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I–converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6. [CrossRef]
  • 20. Bar-Or D, Lau E, Winkler JV. A Novel assay for cobalt-albumin binding and its potential as a marker for myocardıal ıschemıa-a prelımınary report. J Emerg Med 2000; 4: 311-5. [CrossRef]
  • 21. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007; 45: 261-2. [CrossRef]
  • 22. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-85.
  • 23. Enli Y, Türk M, Akbay R, Evrengül H, Tanrıverdi H, Kuru O, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther 2008; 25: 37-44. [CrossRef]
  • 24. Avşar O, Demir I, Ekiz O, Altekin RE, Yalçınkaya S. Relationship between the slow coronary flow and carotid artery intima-media thickness. Anadolu Kardiyol Derg 2007; 7: 19-23.
  • 25. Tanrıverdi H, Evrengül H, Tanrıverdi S, Kuru O, Seleci D, Enli Y, et al. Carotid intima-media thickness in coronary slow flow: relationship with plasma homocysteine levels. Coron Artery Dis 2006; 17: 331-7. [CrossRef]
  • 26. Yaymacı B, Dağdelen S, Bozbuğa N, Demirkol O, Say B, Güzelmeriç F, et al. The response of the myocardial metabolism to atrial pacing in patients with coronary slow flow. Int J Cardiol 2001; 78: 151-6. [CrossRef]
  • 27. Lubrano V, Di Cecco P, Zucchelli GC. Role of superoxide dismutase in vascular inflammation and in coronary artery disease. Clin Exp Med 2006; 6: 84-8. [CrossRef]
  • 28. Fujimoto H, Taguchi J, Imai Y, Ayabe S, Hashimoto H, Kobayashi H, et al. Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur Heart J 2008; 29: 1267-74.
  • 29. Schwenke DC. Antioxidants and atherogenesis. J Nutr Biochem 1998; 9: 424-5. [CrossRef]
  • 30. Sezen Y, Baş M, Polat M, Yıldız A, Büyükhatipoğlu H, Küçükdurmaz Z, et al. The relationship between oxidative stress and coronary artery ectasia. Cardiol J 2010;17:488-94.
  • 31. Nikolic-Heitzler V, Rabuzin F, Tatzber F, Vrkic N, Bulj N, Borovic S, et al. Persistent oxidative stress after myocardial infarction treated by percutaneous coronary intervention. Tohoku J Exp Med 2006; 210: 247-55. [CrossRef]
  • 32. Yao D, Vlessidis AG, Evmiridis NP, Siminelakis S, Dimitra N. Possible mechanism for nitric oxide and oxidative stress induced pathophysiological variance in acute myocardial infarction development. A study by a flow injection-chemiluminescence method. Anal Chim Acta 2004; 505: 115-23. [CrossRef]
  • 33. Türedi S, Karahan SC, Menteşe A, Gündüz A, Topbaş M, Koşucu P, et al. Investigation of relationship between the D-dimer and ischemia-modified albumin levels with the radiological imagingbased pulmonary embolism severity score in acute pulmonary embolism. Anadolu Kardiyol Derg 2010; 10: 346-52. [CrossRef]
  • 34. Üstün Y, Engin-Üstün Y, Öztürk O, Alanbay I, Yaman H. Ischemiamodified albumin as an oxidative stress marker in preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 418-21. [CrossRef]
  • 35. Kalay N, Çetinkaya Y, Başar E, Muhtaroğlu S, Özdoğru I, Gül A, et al. Use of ischemia-modified albumin in diagnosis of coronary artery disease. Coron Artery Dis 2007; 18: 633-7. [CrossRef]
  • 36. Liyan C, Jie Z, Yonghua W, Xiaozhou H. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008; 22: 45-9. [CrossRef]
  • 37. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107: 2403-5. [CrossRef]
  • 38. Gündüz A, Türedi S, Menteşe A, Karahan SC, Hoş G, Tatlı O, et al. Ischemia-modified albumin in the diagnosis of acute mesenteric ischemia: a preliminary study. Am J Emerg Med 2008; 26: 202-5.
  • 39. Gündüz A, Türedi S, Menteşe A, Altunayoğlu V, Turan I, Karahan SC, et al. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008; 26: 874-8.
  • 40. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006; 47: 493-502. [CrossRef]
  • 41. Xanthos T, Iacovidou N, Pantazopoulos I, Vlachos I, Bassiakou E, Stroumpoulis K, et al. Ischemia-modified albumin predicts the outcome of cardiopulmonary resuscitation: An experimental study. Resuscitation 2010; 81: 591-5. [CrossRef]
  • 42. Demirkol MO, Yaymaci B, Mutlu B. Dipyridamole myocardial perfusion single photon emission computed tomography in patients with slow coronary flow. Coron Artery Dis 2002; 13: 223-9. [CrossRef]
  • 43. Goel PK, Gupta SK, Agarwal A, Kapoor A. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 2001; 52: 507-14. [CrossRef]
  • 44. Pilz G, Klos M, Ali E, Hoefling B, Scheck R, Bernhardt P. Angiographic correlations of patients with small vessel disease diagnosed by adenosine-stress cardiac magnetic resonance imaging. J Cardiovasc Magn Reson 2008; 10: 8. [CrossRef]
  • 45. Piva SJ, Duarte MM, Da Cruz IB, Coelho AC, Moreira AP, Tonello R, et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011; 44: 345-7. [CrossRef]
APA KOÇ F, ERDEM S, ALTUNKAŞ F, ÖZBEK K, GÜL E, KURBAN S, TAŞYÜREK E, ERBAY E, SÖĞÜT E (2011). Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study. Anadolu Kardiyoloji Dergisi, 11(7), 582 - 587.
Chicago KOÇ Fatih,ERDEM Sami,ALTUNKAŞ Fatih,ÖZBEK Kerem,GÜL Enes Elvin,KURBAN SEVİL,TAŞYÜREK Erkan,ERBAY Ekrem,SÖĞÜT Erkan Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study. Anadolu Kardiyoloji Dergisi 11, no.7 (2011): 582 - 587.
MLA KOÇ Fatih,ERDEM Sami,ALTUNKAŞ Fatih,ÖZBEK Kerem,GÜL Enes Elvin,KURBAN SEVİL,TAŞYÜREK Erkan,ERBAY Ekrem,SÖĞÜT Erkan Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study. Anadolu Kardiyoloji Dergisi, vol.11, no.7, 2011, ss.582 - 587.
AMA KOÇ F,ERDEM S,ALTUNKAŞ F,ÖZBEK K,GÜL E,KURBAN S,TAŞYÜREK E,ERBAY E,SÖĞÜT E Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study. Anadolu Kardiyoloji Dergisi. 2011; 11(7): 582 - 587.
Vancouver KOÇ F,ERDEM S,ALTUNKAŞ F,ÖZBEK K,GÜL E,KURBAN S,TAŞYÜREK E,ERBAY E,SÖĞÜT E Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study. Anadolu Kardiyoloji Dergisi. 2011; 11(7): 582 - 587.
IEEE KOÇ F,ERDEM S,ALTUNKAŞ F,ÖZBEK K,GÜL E,KURBAN S,TAŞYÜREK E,ERBAY E,SÖĞÜT E "Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: A pilot observational study." Anadolu Kardiyoloji Dergisi, 11, ss.582 - 587, 2011.